NASDAQ · Biotechnology · USD
Design Therapeutics, Inc. (DSGN) Stock Analysis
Design Therapeutics, Inc. (DSGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
DSGN Key Statistics
As of Oct 21, 2026Trading
- Open
- $11.09
- Previous Close
- $11.10
- Day's Range
- 10.65–11.25
- 52-Week Range
- 5.28–17.25
- Volume
- 328.96K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.69
Valuation
- Market Cap
- $671.50M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.18
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$69.79M
- Shares Outstanding
- 62.58M
- 1-Year Return
- +90.59%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 604.80K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, DSGN closed at $10.73, +90.59% over 1 year.
Design Therapeutics, Inc. (DSGN) has a market capitalization of $671.50M.
In fiscal 2025, DSGN reported revenue of $0.00.
DSGN Stock Return by Calendar Year
Design Therapeutics, Inc. (DSGN) return since Mar 2021: what $10,000 became
- 1 year
- $10,000 $19,059
- +90.59%
- 5 years
- $10,000 $7,344
- −26.56%
- Since Mar 2021
- $10,000 $3,155
- −68.45%
If you had invested $10,000 in Design Therapeutics, Inc. (DSGN) at the close on March 29, 2021, the earliest close on record here, it would have been worth $3,155 at the close on October 21, 2026: −68.45% in total, −18.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +14.39% |
| 2025 | +52.03% |
| 2024 | +132.83% |
| 2023 | −74.17% |
| 2022 | −52.08% |
| 2021 (partial year) | −37.05% |
As of October 21, 2026.
DSGN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$69.79M | — |
| 2024 | $0.00 | −$49.59M | — |
| 2023 | $0.00 | −$66.86M | — |
| 2022 | $0.00 | −$63.31M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$79.47M | −$69.79M | — |
| 2024 | $0.00 | — | −$62.38M | −$49.59M | — |
| 2023 | $0.00 | — | −$78.19M | −$66.86M | — |
| 2022 | $0.00 | — | −$67.59M | −$63.31M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
SeekingAlphaWells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
BenzingaDesign Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
YahooDesign Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
BenzingaA Deeper Dive Into Design Therapeutics
SeekingAlpha
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B